CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 
 
 


Stemline Therapeutics Inc  (STML)
Other Ticker:  
 
    Sector  Healthcare    Industry Major Pharmaceutical Preparations
 
 

STML's Income from Cont. Operations Growth by Quarter and Year

Stemline Therapeutics Inc's Income from Cont. Operations results by quarter and year




STML Income from Cont. Operations (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - -21.75 -10.01 -10.18
III Quarter September - -16.06 -9.92 -9.23
II Quarter June - -15.46 -9.32 -10.15
I Quarter March -18.42 -14.57 -9.05 -7.68
FY   -18.42 -67.84 -38.30 -37.24



STML Income from Cont. Operations first quarter 2018 Y/Y Growth Comment
Stemline Therapeutics Inc in the first quarter recorded loss from continued operations of $ -18.42 millions.

According to the results reported in the first quarter, Stemline Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Stemline Therapeutics Inc' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter.




STML Income from Cont. Operations ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Stemline Therapeutics Inc's first quarter 2018 Income from Cont. Operations $ -18.42 millions STML's Income Statement
Stemline Therapeutics Inc's first quarter 2017 Income from Cont. Operations $ -14.57 millions Quarterly STML's Income Statement
New: More STML's historic Income from Cont. Operations Growth >>


STML Income from Cont. Operations (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations first quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2015, 2016, 2017, 2018
You need to upgrade your Flash Player

Stemline Therapeutics Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


STML's I. Quarter Q/Q Income from Cont. Operations Comment
Even if Stemline Therapeutics Inc in the I. Quarter 2018 showed loss from continued operations of $ -18.42 millions, some analyst said, that current results are recovery relative to the -21.75 millions in the forth quarter.

Within Major Pharmaceutical Preparations industry Stemline Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Stemline Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Stemline Therapeutics Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
12 Months Ending
(Jun 30 2017)
12 Months Ending
(Mar 31 2017)
Cumulative Income from Cont. Operations 12 Months Ending $ -71.68 $ -67.83 $ -56.09 $ -49.96 $ -43.82
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Stemline Therapeutics Inc' has realized cumulative trailing twelve months loss from continued operations of $ -72 millions in the Mar 31 2018 period.
The business is worsening as the cumulative loss from continued operations is inflating from $ -67.83 millions for the period from Dec 31 2017 to Mar 31 2017 and $ -21.75 millions for the twelve months ending in the quarter Mar 31 2017.

Stemline Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #


You need to upgrade your Flash Player




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
STML's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for STML's Competitors
Income from Cont. Operations Growth for Stemline Therapeutics Inc's Suppliers
Income from Cont. Operations Growth for STML's Customers

You may also want to know
STML's Annual Growth Rates STML's Profitability Ratios STML's Asset Turnover Ratio STML's Dividend Growth
STML's Roe STML's Valuation Ratios STML's Financial Strength Ratios STML's Dividend Payout Ratio
STML's Roa STML's Inventory Turnover Ratio STML's Growth Rates STML's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2018 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2018
Luminex Corp  45.64 %$ 45.639 millions
Neurometrix, Inc.  44.11 %$ 44.109 millions
Baxter International Inc  42.49 %$ 42.491 millions
Integrated Biopharma Inc  39.31 %$ 39.308 millions
Align Technology Inc  38.10 %$ 38.096 millions
Tivity Health, Inc.  37.82 %$ 37.821 millions
United Therapeutics Corp  36.90 %$ 36.898 millions
Dentsply Sirona Inc.  35.85 %$ 35.846 millions
Petmed Express Inc  35.72 %$ 35.719 millions
Mylan N.v.  31.17 %$ 31.175 millions
Idexx Laboratories Inc  29.57 %$ 29.566 millions
Jrsis Health Care Corp  27.75 %$ 27.754 millions
Bruker Corp  26.27 %$ 26.267 millions
Abaxis Inc  25.83 %$ 25.825 millions
Resmed Inc  25.39 %$ 25.394 millions
Encompass Health Corp  24.79 %$ 24.793 millions
Stereotaxis, Inc.  23.56 %$ 23.561 millions
Vistagen Therapeutics, Inc.  22.61 %$ 22.606 millions
American Shared Hospital Services  19.93 %$ 19.926 millions
Biospecifics Technologies Corp  18.95 %$ 18.951 millions
Mednax, Inc.  15.98 %$ 15.975 millions
Abbott Laboratories  15.86 %$ 15.864 millions
Utah Medical Products Inc  15.72 %$ 15.724 millions
Cambrex Corp  14.84 %$ 14.843 millions
Addus Homecare Corp  14.06 %$ 14.064 millions
Artemis Therapeutics, Inc.  14.05 %$ 14.054 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ZZLL's Profile

Stock Price

ZZLL's Financials

Business Description

Fundamentals

Charts & Quotes

ZZLL's News

Suppliers

ZZLL's Competitors

Customers & Markets

Economic Indicators

ZZLL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us



CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071